RXST - Earnings announcements

ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 unitsRobust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustabilityRecent regulatory approval in New Zealand furthering the company's international footprint and global market opportunity2026 sales and gross margin guidance u

ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link s

ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practiceLight Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong foundation for future procedure growthRxSight's FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from conte

ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we

ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2025. Key Financial Highlights Reported third quarter 2025 revenue of $30.3 million, representing a decrease of 14% compared to the third quarter of 2024, reflecting: The sale of 26,045 Light Adjustable Lenses (LAL®/LAL+®), representing a 6% increase in procedure volume compared to the third quarter of 2024;The sale of 25 Light Delivery Devices (LDD™s), representing a 68% decrease compared to the third

ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the third quarter of 2025 after the market close on Wednesday, November 5, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 6619966. The call will also be broadcast live in listen-only mode via a link on the company's investor relations

ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights Reported second quarter 2025 revenue of $33.6 million, representing a decrease of 4% compared to the second quarter of 2024, reflecting: The sale of 27,380 Light Adjustable Lenses (LAL®/LAL+®), representing a 13% increase in procedure volume compared to the second quarter of 2024;The sale of 40 Light Delivery Devices (LDD™s), representing a 49% decrease compared to the sec

ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we

ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is expected to be approximately $33.6 million, representing a decrease of 4% compared to the prior year period, and a decrease of 11% compared to the first quarter of 2025, driven by: The

ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations web

ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, representing growth of 28% compared to the prior year period, and a decrease of 6% compared to the fourth quarter of 2024, driven by: The sale

ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024. Key Quarterly and Full-Year Highlights Recognized fourth quarter 2024 revenue of $40.2 million, an increase of 41% compared to the fourth quarter of 2023, reflecting: The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®), representing an 61% increase in procedure volume compared to the fourth quarter of 2023; andThe sale of 83 Light Delivery Devices (LDD™s), expanding the installed base to

ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 7159871. The call will also be broadcast live in listen-only mode via a link on the company's investor r

ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an 80% increase in procedure volume compared to the third quarter of 2023; andThe sale of 78 Light Delivery Devices (LDD™s), representing a 18% increase in unit sales compared to

ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (888) 596-4144 or (646) 968-2525, and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company's investor re

ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applicati

ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+™), representing a 92% increase in procedure volume compared to the first quarter of 2023;The sale of 66 Light Delivery Devices (LDD™s), representing an 18% increase in unit sales compar

ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applications are

ALISO VIEJO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2023. Key Quarterly and Full Year Highlights Recognized fourth quarter 2023 revenue of $28.6 million, an increase of 78% compared to the fourth quarter of 2022, reflecting: The sale of 77 Light Delivery Devices (LDD™s), representing a 35% unit increase from the fourth quarter of 2022, expanding the installed base to 666 LDDs at the end of the quarter, a 67% increase compared to the 400-uni

ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Wednesday, February 28, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is r

ALISO VIEJO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: The sale of 66 Light Delivery Devices (LDD™s), representing a 35% increase in unit sales compared to the third quarter of 2022 and expanding the installed base to 589 LDDs at the end of the quarter, representing a 72% i

ALISO VIEJO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter 2023 after the market close on Thursday, November 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended that par

ALISO VIEJO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2023. Key Quarterly Highlights Reported second quarter 2023 revenue of $20.8 million, an increase of 83% compared to the second quarter of 2022, reflecting: The sale of 67 Light Delivery Devices (LDD™s), representing a 37% increase in unit sales compared to the second quarter of 2022 and expanding the installed base to 523 LDDs at the end of the quarter, representing a 78% increase compared to end of the second qu

ALISO VIEJO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter 2023 after the market close on Monday, August 7, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended that partic

ALISO VIEJO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended that particip

ALISO VIEJO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and fiscal year 2022 after the market close on Monday, March 6, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommen

ALISO VIEJO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three and nine months ended September 30, 2022. Key Quarterly Highlights: Delivered third quarter 2022 revenue of $12.6 million, an increase of 118% compared to the third quarter of 2021, reflecting: The sale of 49 Light Delivery Devices (LDD™s), representing a 58% unit increase from the third quarter of 2021, expanding the installed base to 343 LDDs at the end of the quarter, a 113% increase compared to the 161-unit LDD installed base at the end of the

ALISO VIEJO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended that participants join ten minut

ALISO VIEJO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2022. Key Quarterly Highlights: Delivered second quarter 2022 revenue of $11.4 million, an increase of 132% compared to the second quarter of 2021, reflecting: The sale of 49 Light Delivery Devices (LDD™s), representing a 96% unit increase from the second quarter of 2021, expanding the installed base to 294 LDDs at the end of the quarter, a 126% increase compared to the 130-unit LDD installed base at the end

ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 after the market close on Monday, August 8, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. Participants may register for the ca

ALISO VIEJO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – April 21, 2022 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the first quarter 2022 after the market close on Thursday, May 5, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also b

ALISO VIEJO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months and fiscal year ended December 31, 2021. Recent Highlights Achieved fourth quarter 2021 revenue of $8.4 million, representing growth of 71% compared to the prior year period and 46% growth over the third quarter of 2021 driven by the: Sale of 45 Light Delivery Devices (LDD™s), expanding the installed base to 206 LDDs as of December 31, 2021; andSale of 2,959 Light Adjustable Lenses (LAL®s). Achieved fiscal year 2021 revenue of $2

ALISO VIEJO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the fourth quarter and fiscal year 2021 after the market close on Tuesday, March 8, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also b

ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also be available by dialing 844-602-7038 (U.S.) or 916-637-9714 (International) five to ten minutes pr

ALISO VIEJO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ:RXST) an ophthalmic medical device company, today announced an updated date for reporting second quarter 2021 financial results. In observance of the Rosh Hashanah holiday, the company will now report after the market close on Thursday, September 9, 2021. Management will discuss the results during a conference call beginning that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://investors.rxsight.com/. About RxSight, Inc.RxSight, Inc. is a commercial-stage medical techno

ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the market close on Tuesday, September 7, 2021. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://investors.rxsight.com/. About RxSight, Inc.RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.